After treatment: surveillance and survivorship
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
Most people finishing treatment for HIV-associated lymphoma are in remission, and the immediate question becomes what happens now.
Two sets of follow-up resume at once: cancer surveillance, concentrated in the first two years, and HIV care, which never stopped but now has immune recovery to track.
Related pages: AIDS-related lymphoma
The bottom line
- Most lymphoma relapses occur within the first two years.
- CD4 counts recover over months to years after chemotherapy.
- Prophylaxis stops based on CD4 recovery rather than on the end of chemotherapy.
- People with HIV remain at higher risk of several other cancers.
- How long cancer surveillance should continue, which guidelines set conservatively.
- Why immune recovery after chemotherapy varies so much between people.
The story, step by step
What the evidence labels mean
What follow-up involves
What happens
The cancer side.
What the research shows
- Follow-up is clinical examination plus blood tests, typically every 3 months for the first year or two, then less often.
- Imaging is used selectively. Routine surveillance PET-CT in people in remission is no longer recommended in most settings, because it produces false alarms and radiation exposure without improving outcomes. A scan is done when something changes.
- Most relapses occur within the first two years and are usually found because of a symptom rather than a scan.
- Report new lumps, drenching night sweats, unexplained fever, unintended weight loss, or new pain that does not settle, rather than waiting for the next appointment.
- The anxiety before each appointment is near-universal and is treatable rather than something to endure.
- A relapse is not the end of options. Second-line chemotherapy, autologous stem cell transplant and CAR-T therapy are all used in people with HIV.
Why it matters
Knowing that scans are not the main way relapse is found makes the gap between appointments less frightening for many people.
What's still uncertain
- The best surveillance interval and duration, which differs between guidelines.
Read more
- National Cancer Institute: AIDS-related lymphoma treatment (PDQ)Government
- National Cancer Institute: Survivorship and late effectsGovernment
- Leukemia & Lymphoma SocietyNonprofit
Next: Immune recovery
CD4 counts and stopping prophylaxis
What happens
The HIV side of recovery.
What the research shows
- CD4 counts fall during chemotherapy and recover afterwards over months, sometimes a year or more. Recovery is often slower than people expect and slower than viral suppression returns.
- Prophylaxis against Pneumocystis and other opportunistic infections continues until the CD4 count has recovered and stayed up, not until the last chemotherapy cycle.
- Stopping prophylaxis early is a recognized route to a preventable infection, and it usually happens because nobody said when to stop.
- Viral load should return to undetectable if it ever rose during treatment, and a persistently detectable viral load is investigated rather than accepted.
- A full revaccination plan is needed after chemotherapy, because treatment with rituximab in particular depletes the B-cells that hold vaccine memory. Timing depends on B-cell and CD4 recovery.
- Live vaccines remain contraindicated until immune recovery is established.
Why it matters
Immune recovery runs on its own timetable, and the prophylaxis stops when the numbers say so rather than when treatment ends.
What's still uncertain
- How long immune reconstitution takes after rituximab-containing regimens in people with HIV.
Read more
- HHS: Guidelines for opportunistic infections in adults and adolescents with HIVGovernment
- National Cancer Institute: AIDS-related lymphoma treatment (PDQ)Government
- CDC: HIV and cancerGovernment
Next: Late effects
What is monitored, and for how long
What happens
The long tail of treatment.
What the research shows
- Anthracycline chemotherapy, such as doxorubicin, carries a long-term risk of heart muscle damage, and cardiac monitoring is recommended for people who received significant doses.
- Cardiovascular risk is already elevated in HIV, and the two add. Blood pressure, lipids, glucose and weight are watched, and the REPRIEVE trial result on statins applies here too.
- Peripheral neuropathy from vincristine often improves slowly and sometimes persists. It is treatable and worth raising.
- Second cancers are more likely after chemotherapy and radiation, including treatment-related myelodysplastic syndrome, and generally appear years later.
- People with HIV remain at higher risk of several HPV-related cancers, so cervical and anal screening stay relevant, as does lung cancer risk if there is a smoking history.
- Thyroid, bone density, hormone and fertility effects depend on what was given, particularly after radiation.
- Ask for a written survivorship care plan listing treatments, doses, what is monitored and how often. It is what makes any of this trackable.
Why it matters
The shift after treatment is from infection risk to ordinary preventive medicine done earlier and more attentively, which is also the shape of long-term HIV care.
What's still uncertain
- How much the combined cardiovascular risk of HIV and anthracyclines compounds, which is being studied.
Read more
- National Cancer Institute: Survivorship and late effectsGovernment
- HHS: Clinical guidelines for antiretroviral therapy in adults and adolescentsGovernment
- National Cancer Institute: AIDS-related lymphoma treatment (PDQ)Government
Next: Life afterwards
Work, energy and the fear
What happens
Returning, which takes longer than people expect.
What the research shows
- Energy returns over 6 to 12 months, and longer after intensive regimens. Planning a staged return to work is more realistic than a full return on week one.
- Exercise remains the best-evidenced treatment for persistent fatigue, and a cancer rehabilitation referral helps people start safely.
- Fear of recurrence peaks around appointments and scans and is near-universal. Psycho-oncology services treat it effectively, and it is not a sign of ingratitude.
- Stopping smoking is the highest-value single action afterwards, for second cancer risk, cardiovascular risk and lung cancer risk, all of which are already raised in HIV.
- Support drops away when treatment ends, exactly when many people feel worst. Saying so to the people around you helps more than waiting for them to notice.
- The outlook is genuinely good and worth repeating: outcomes in HIV-associated lymphoma now approach those of people without HIV, and most people treated for it are cured.
Why it matters
The hardest stretch for many people is the first few months after treatment ends, when the structure disappears and everyone assumes it is over.
What's still uncertain
- Which survivorship interventions help most, where evidence is thin across cancers.